The increased signaling of PI3K p110β isoform due to the acquired loss of function of PTEN was first clinically described in breast cancer by longitudinal analysis of multiple metastases on an HR-positive breast cancer patient with an initial robust response to alpelisib [240,246]. This evidence concerns the gene PTEN and breast carcinoma.